A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, H Brashear R, Novak G
J Alzheimers Dis. 2016 Oct 18; 54(4):1509-1519. PMID: 27589523. Abstract